Another week, another round of developments across psychedelic medicine. Below is our recap of what mattered to investors for the week of June 29 – July 5, 2026.
Cybin Inc. (d/b/a Helus Pharma) (HELP): Helus Pharma reports FY2026 results with APPROACH Phase 3 enrollment above 88%
Cybin, operating as Helus Pharma, released fiscal-year 2026 results and a business update, reporting that enrollment in its pivotal Phase 3 APPROACH study of HLP003 for adjunctive major depressive disorder had passed 88%, keeping a topline readout on track for Q4 2026. Phase 2 data previously showed roughly a 23-point MADRS improvement at 12 months after two doses. The update reinforces the company's positioning as a late-stage psychedelics developer following its 2026 Nasdaq uplisting and rebrand.
Source: globenewswire.com
AtaiBeckley Inc. (ATAI): AtaiBeckley added to Russell 2000 and Russell 3000 indexes
AtaiBeckley was added to the Russell 2000 and Russell 3000 indexes in the FTSE Russell annual reconstitution effective June 29, 2026. Index inclusion typically brings passive-fund buying and broader institutional visibility. The addition marks a milestone for the merged psychedelic mental-health company as it advances Phase 3-bound programs including BPL-003.
Source: stocktitan.net
Optimi Health Corp. (OPTH): Optimi Health completes third commercial psilocybin export to Australia
Optimi Health completed another export of 5mg psilocybin capsules, about 1,000 capsules, to Australia for treatment-resistant depression patients, its third commercial shipment since launching the product in September 2025. The recurring shipments demonstrate steady demand and Optimi's ability to reliably supply the regulated Australian prescription market. The order flow supports the commercial-stage manufacturer's revenue base.
Source: globenewswire.com
U.S. Congress (federal policy): Bipartisan IBOGAINE Act introduced to codify Trump psychedelics executive order
Reps. Michael McCaul (R-TX) and Morgan Luttrell (R-TX), joined by Lou Correa (D-CA) and Jack Bergman (R-MI), introduced the IBOGAINE Act to accelerate development of and access to psychedelic therapies for serious mental illness. The bill would direct the attorney general to decide within 60 days whether to move ibogaine from Schedule I to Schedule II and would require rescheduling proceedings for any Schedule I substance that completes Phase 3 trials. The legislation would enshrine President Trump's psychedelics executive order into federal law, a potential catalyst for the sector.
Source: marijuanamoment.net
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.